Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis.

Addeo A, Banna GL, Metro G, Di Maio M.

Ann Oncol. 2019 Apr;30 Suppl 2:ii57. doi: 10.1093/annonc/mdz063.051. No abstract available.

2.

Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial.

Passaro A, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Migliorino MR, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina GZ, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D, De Marinis F.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.013. No abstract available.

3.

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

Ricciuti B, Lamberti G, Roila F, Metro G.

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S378-S382. doi: 10.21037/tlcr.2019.04.15. No abstract available.

4.

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.

Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G.

J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23.

5.

Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).

Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group.

Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Review. No abstract available.

6.

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

Metro G, Signorelli D.

Lung Cancer Manag. 2020 Jan 16;8(4):LMT18. doi: 10.2217/lmt-2019-0012. No abstract available.

7.

Correction to: Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Carosi M, Casini B, Metro G, Maschio M, Koudriavtseva T, Cognetti F, Fabi A.

J Neurooncol. 2019 Oct;145(1):189. doi: 10.1007/s11060-019-03285-x.

PMID:
31502041
8.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
9.

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.

Ricciuti B, Brambilla M, Cortellini A, De Giglio A, Ficorella C, Sidoni A, Bellezza G, Crinò L, Ludovini V, Baglivo S, Metro G, Chiari R.

Clin Transl Oncol. 2019 Jul 22. doi: 10.1007/s12094-019-02175-y. [Epub ahead of print]

PMID:
31332704
10.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
11.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.

J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4. Erratum in: J Neurooncol. 2019 Sep 9;:.

PMID:
31273578
12.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).

Facchinetti F, Pilotto S, Metro G, Baldini E, Bertolaccini L, Cappuzzo F, Delmonte A, Gasparini S, Inno A, Marchetti A, Passiglia F, Puma F, Ricardi U, Rossi A, Crinò L, Novello S.

Tumori. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418.

PMID:
31264531
13.

Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma.

Chen R, Xia W, Wang S, Xu Y, Ma Z, Xu W, Zhang E, Wang J, Fang T, Zhang Q, Dong G, Cho WC, Ma PC, Brandi G, Tavolari S, Ujhazy P, Metro G, Popper HH, Yin R, Qiu M, Xu L.

Mol Ther Nucleic Acids. 2019 Jun 7;16:543-553. doi: 10.1016/j.omtn.2019.04.004. Epub 2019 Apr 13.

14.
15.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R.

Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27. Erratum in: Clin Lung Cancer. 2020 Feb 14;:.

PMID:
30910574
16.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21.

PMID:
30885550
17.

Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?

Chiari R, Sidoni A, Metro G.

J Thorac Dis. 2018 Nov;10(Suppl 33):S3890-S3894. doi: 10.21037/jtd.2018.10.22. No abstract available.

18.

KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Ludovini V, Ricciuti B, Tofanetti FR, Mencaroni C, Giannarelli D, Sidoni A, Reda MS, Siggillino A, Baglivo S, Crinò L, Bellezza G, Chiari R, Metro G.

Mol Clin Oncol. 2018 Dec;9(6):689-696. doi: 10.3892/mco.2018.1731. Epub 2018 Oct 1.

19.

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.

Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R.

J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

PMID:
30506406
20.

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A.

Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.

PMID:
30448912
21.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S294-S296. doi: 10.21037/tlcr.2018.07.12. No abstract available.

22.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S290-S293. doi: 10.21037/tlcr.2018.07.11. No abstract available.

23.

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.

Ricciuti B, Marcomigni L, Metro G, Bellezza G, Caselli E, Baglivo S, Chiari R.

J Thorac Oncol. 2018 Nov;13(11):e220-e222. doi: 10.1016/j.jtho.2018.05.035. No abstract available.

24.

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Metro G, Baglivo S, Siggillino A, Ludovini V, Chiari R, Rebonato A, Bellezza G.

Clin Drug Investig. 2018 Oct;38(10):983-987. doi: 10.1007/s40261-018-0691-8.

PMID:
30151614
25.

Osimertinib.

Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G.

Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. Review.

PMID:
30069773
26.

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.

Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, Chiari R.

J Thorac Oncol. 2018 Aug;13(8):e145-e147. doi: 10.1016/j.jtho.2018.03.017. No abstract available.

27.

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Addeo A, Metro G.

Drugs Context. 2018 Jul 10;7:212537. doi: 10.7573/dic.212537. eCollection 2018.

28.

EGFR targeted therapy for lung cancer: are we almost there?

Metro G.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S142-S145. doi: 10.21037/tlcr.2018.03.11. No abstract available.

29.

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maiettini D, Chiari R.

Lung Cancer. 2018 Jun;120:70-74. doi: 10.1016/j.lungcan.2018.04.002. Epub 2018 Apr 3.

PMID:
29748019
30.

Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients.

Metro G, Giannarelli D, Sidoni A, Chiari R, Bellezza G.

Int J Biol Markers. 2018 Apr 1:1724600818754763. doi: 10.1177/1724600818754763. [Epub ahead of print] No abstract available.

PMID:
29683065
31.

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R.

Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4. Review.

PMID:
29666949
32.

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?

De Giglio A, Porreca R, Brambilla M, Metro G, Prosperi E, Bellezza G, Pirro M, Chiari R, Ricciuti B.

Thromb Res. 2018 Mar;163:51-53. doi: 10.1016/j.thromres.2017.12.004. Epub 2017 Dec 9. No abstract available.

PMID:
29353684
33.

Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.

Tazza M, Metro G.

J Thorac Dis. 2017 Oct;9(10):4064-4069. doi: 10.21037/jtd.2017.08.130. Review.

34.

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

Ricciuti B, Metro G, Brambilla M, Ludovini V, Baglivo S, Siggillino A, Prosperi E, Chiari R.

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025. No abstract available.

35.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R.

Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

PMID:
29135281
36.

Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma.

Bellezza G, Vannucci J, Bianconi F, Metro G, Del Sordo R, Andolfi M, Ferri I, Siccu P, Ludovini V, Puma F, Sidoni A, Cagini L.

Interact Cardiovasc Thorac Surg. 2017 Dec 1;25(6):856-861. doi: 10.1093/icvts/ivx202.

PMID:
29106595
37.

Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Rebonato A, Graziosi L, Maiettini D, Marino E, De Angelis V, Brunese L, Mosca S, Metro G, Rossi M, Orgera G, Scialpi M, Donini A.

Gastroenterol Res Pract. 2017;2017:4164130. doi: 10.1155/2017/4164130. Epub 2017 Aug 15.

38.

Erratum to: CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles.

Rebonato A, Maiettini D, Andolfi M, Fischer MJ, Vannucci J, Metro G, Basile A, Duranti M, Rossi M.

Cardiovasc Intervent Radiol. 2018 Jan;41(1):202. doi: 10.1007/s00270-017-1781-3. No abstract available.

PMID:
28861589
39.

CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles.

Rebonato A, Maiettini D, Andolfi M, Fischer MJ, Vannucci J, Metro G, Basile A, Rossi M, Duranti M.

Cardiovasc Intervent Radiol. 2018 Feb;41(2):284-290. doi: 10.1007/s00270-017-1768-0. Epub 2017 Aug 14. Erratum in: Cardiovasc Intervent Radiol. 2017 Aug 31;:.

PMID:
28808757
40.

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.

Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A, Rebonato A, Messina S, Crinò L, Chiari R.

Mayo Clin Proc. 2017 Aug;92(8):1304-1311. doi: 10.1016/j.mayocp.2017.03.022.

PMID:
28778263
41.

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.

Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G.

Ther Adv Med Oncol. 2017 Jun;9(6):387-404. doi: 10.1177/1758834017702820. Epub 2017 Apr 16. Review.

42.

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S.

Tumori. 2017 Sep 18;103(5):405-421. doi: 10.5301/tj.5000625. Epub 2017 May 10. Review.

PMID:
28497847
43.

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.

Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M, Chiari R.

Med Oncol. 2017 Jun;34(6):105. doi: 10.1007/s12032-017-0967-5. Epub 2017 Apr 25. Review.

PMID:
28444624
44.

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.

Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, Paglialunga L.

J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027. No abstract available.

45.

Optimal management of ALK-positive NSCLC progressing on crizotinib.

Metro G, Tazza M, Matocci R, Chiari R, Crinò L.

Lung Cancer. 2017 Apr;106:58-66. doi: 10.1016/j.lungcan.2017.02.003. Epub 2017 Feb 6. Review.

PMID:
28285695
46.

Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".

Metro G, Chiari R.

Transl Lung Cancer Res. 2016 Dec;5(6):561-562. doi: 10.21037/tlcr.2016.12.04. No abstract available.

47.

Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment.

Maiettini D, De Angelis V, Graziosi L, Rebonato S, Falcinelli L, Metro G, Rebonato A.

Recenti Prog Med. 2016 Dec;107(12):673-676. doi: 10.1701/2502.26238.

PMID:
27997010
48.

The safety of nivolumab for the treatment of advanced non-small cell lung cancer.

Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R.

Expert Opin Drug Saf. 2017 Jan;16(1):101-109. Epub 2016 Dec 11. Review.

PMID:
27910704
49.

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Ricciuti B, Metro G, Leonardi GC, Sordo RD, Colella R, Puma F, Ceccarelli S, Potenza R, Rebonato A, Maiettini D, Crinò L, Chiari R.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000514.

PMID:
27133228
50.

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient.

Ricciuti B, Leonardi GC, Ravaioli N, De Giglio A, Brambilla M, Prosperi E, Ribacchi F, Meacci M, Crinò L, Maiettini D, Chiari R, Metro G.

J Breast Cancer. 2016 Sep;19(3):324-329. Epub 2016 Sep 23.

Supplemental Content

Support Center